195 related articles for article (PubMed ID: 25530587)
1. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
An SG; Kim DU; Song GA; Jang AL
Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
5. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
[TBL] [Abstract][Full Text] [Related]
7. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
[TBL] [Abstract][Full Text] [Related]
8. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
[TBL] [Abstract][Full Text] [Related]
9. Survival and prognostic factors of unresectable pancreatic cancer.
Park JK; Yoon YB; Kim YT; Ryu JK; Yoon WJ; Lee SH
J Clin Gastroenterol; 2008 Jan; 42(1):86-91. PubMed ID: 18097296
[TBL] [Abstract][Full Text] [Related]
10. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
11. Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Inal A; Ciltas A; Yildiz R; Berk V; Kos FT; Dane F; Unek IT; Colak D; Ozdemir NY; Buyukberber S; Gumus M; Ozkan M; Isikdogan A
Asian Pac J Cancer Prev; 2012; 13(5):1841-4. PubMed ID: 22901133
[TBL] [Abstract][Full Text] [Related]
12. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
Altwegg R; Ychou M; Guillaumon V; Thezenas S; Senesse P; Flori N; Mazard T; Caillo L; Faure S; Samalin E; Assenat E
World J Gastroenterol; 2012 Mar; 18(12):1357-64. PubMed ID: 22493549
[TBL] [Abstract][Full Text] [Related]
13. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
[TBL] [Abstract][Full Text] [Related]
14. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
[TBL] [Abstract][Full Text] [Related]
15. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
Fujino Y; Ueda T; Kamigaki T; Takase S; Ajiki T; Kamoda Y; Matsumoto I; Yasuda T; Kuroda Y
Pancreas; 2007 Apr; 34(3):335-9. PubMed ID: 17414056
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
Otake A; Tsuji D; Taku K; Kawasaki Y; Yokoi M; Nakamori H; Osada M; Matsumoto M; Inoue K; Hirai K; Itoh K
Eur J Clin Pharmacol; 2017 Aug; 73(8):1033-1039. PubMed ID: 28487999
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer.
Moon do C; Lee HS; Lee YI; Chung MJ; Park JY; Park SW; Song SY; Chung JB; Bang S
Yonsei Med J; 2016 Sep; 57(5):1124-30. PubMed ID: 27401642
[TBL] [Abstract][Full Text] [Related]
20. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
Ren J; Wu S; Su T; Ding J; Chen F; Li J; Wang Z; Han L; Wu Z
Cancer Med; 2024 May; 13(9):e7229. PubMed ID: 38698688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]